# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Locke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN001-SYN-TD
- Date: 1692-10-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Prudence Hartwell-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Asthma review two weeks after a cold with a yellow-zone flare. **S**

## History of present illness

Mr. Locke returns two weeks after his sick visit for a cold that triggered a yellow-zone flare. He took up to 11 inhalations of budesonide-formoterol on the worst day and never needed prednisolone. His peak flow climbed back above 400 L/min by the fifth day and has been 420 to 440 since. The cold cleared in about a week, and he stopped acetaminophen after four days. The review planned for one week after the sick visit did not take place: the clinic's first slot was today. He now needs his reliever about once a week, sleeps through the night, and has no side effects from tiotropium (no dry mouth, difficulty passing urine, or eye pain). The open fires remain out of use. He would like his first zoster vaccine today. **S**

| Element | Detail |
|---|---|
| Flare | Yellow zone with a cold; managed by the action plan without prednisolone |
| Peak flow | Back to 420 to 440 L/min; 430 in clinic today |
| Reliever use | About once a week |
| Tiotropium | Four months; no side effects |
| Asthma Control Test | 21 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy back to normal |
| Respiratory | Negative | No cough, wheeze, or night waking now; breathless only on steep hills |
| Genitourinary | Negative | No difficulty passing urine |
| Eyes | Negative | No eye pain or blurred vision |

4 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**
- Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 62.8 kg; BMI 19.8 kg/m². All vital signs are synthetic.

Peak expiratory flow: 430 L/min; Asthma Control Test: 21. All results are synthetic.

## Change since baseline

- Asthma Control Test: 12 at baseline, 21 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Respiratory | Clear on quiet and forced breathing; oxygen saturation 97 percent |
| Mouth | No candidiasis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma with persistent airflow limitation, type 2 phenotype** (J45.40). Well controlled (Asthma Control Test 21; reliever about once a week; no night symptoms) on budesonide-formoterol with tiotropium. One yellow-zone flare with a cold, managed correctly by his action plan without oral corticosteroids. Too soon after a flare, and with persistent airflow limitation, to step down; reconsider after three months of good control. **S**
   - Continue budesonide-formoterol two inhalations twice daily plus as needed and tiotropium two inhalations daily.
   - Action plan reviewed; unchanged.
   - After any future flare, the clinic books a review within one week.
   - Recombinant zoster vaccine dose 1 today; dose 2 in two to six months.
   - Asthma review in three months; spirometry within a year of the last.
2. **Acute viral upper respiratory infection with a yellow-zone flare** (J06.9). Resolved. **S**
   - No further action.
3. **Exposure to air pollution and indoor solid-fuel smoke** (Z77.110). Exposure plan maintained; heating season starting. **S**
   - Keep the open fires out of use through the winter; replace the HEPA filters as the maker advises.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 21: well controlled |
| Imaging | Peak expiratory flow | At each visit after a flare, and at home with symptoms | Completed today | 430 L/min in clinic, 98 percent of his best |
| Survey | Review within one week after a flare | Within one week of any exacerbation | Deferred | Missed: the one-week review planned at the sick visit was not booked because no slot was free, and no telephone check was arranged. No harm resulted: his diary shows the peak flow back above 400 L/min by the fifth day without prednisolone. Corrective action: the clinic now books a review within one week, by telephone if no slot is free, whenever he calls or is seen for a flare, and this is written into his care plan |
| Survey | Review 1 to 3 months after a controller change, with an Asthma Control Test | 1 to 3 months after starting or changing controller treatment | Deferred | Partly missed: the twelve-week plan set the full review with an Asthma Control Test at four months, beyond the protocol's 1 to 3 months. The preventive visit at 13 weeks reviewed his symptoms, reliever use, and side effects, but no Asthma Control Test was recorded until today. No harm: he was well controlled at that visit and today. Corrective action: an Asthma Control Test is recorded at any visit where asthma is reviewed |
| Examination | Inhaler technique with his own devices | Every visit | Completed today | Both inhalers used correctly |
| Medication safety | Adherence and reliever use | Every visit | Completed today | No missed doses since the flare; reliever about once a week |
| Medication safety | Tiotropium side effects (dry mouth, urinary retention, angle-closure glaucoma symptoms) | After starting and at each visit | Completed today | None |
| Survey | Exacerbation history | Every visit | Completed today | One yellow-zone flare with a cold; no oral corticosteroids, emergency visits, or admissions |
| Self-management | Trigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergens | Every visit | Completed today | Open fires out of use; HEPA air cleaners running; air quality index checked before city trips; no new exposures |
| Self-management | Smoking and vaping status | Every visit | Completed today | Never smoker; no vaping; no secondhand smoke |
| Self-management | Written asthma action plan | Every visit and after every flare | Completed today | Reviewed after the flare; he used it correctly; unchanged |
| Medication safety | Step-up and step-down assessment | Every visit | Completed today | Well controlled at step 5 (add-on tiotropium); no step-down so soon after a flare; reconsider after three months of good control |
| Imaging | Spirometry | Every 1 to 2 years once stable | Up to date | Last done four months ago; next within a year |
| Imaging | FeNO | To monitor inhaled-corticosteroid response when needed | Not indicated | Low on treatment four months ago; control is good |
| Examination | Comorbidity surveillance | At diagnosis and at least yearly | Up to date | Screened at diagnosis; PHQ-2 0 at the preventive visit |
| Self-management | Vaccination status | Yearly | Completed today | Influenza, COVID-19, and RSV vaccines given five weeks ago; zoster dose 1 today |
| Medication safety | Biologic candidacy | When asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and technique | Not indicated | No exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment |

## Goal progress

- Cause of the cough and breathlessness established by the second visit. Outcome by 1692-03-26: Asthma with persistent airflow limitation confirmed by spirometry, FeNO, eosinophils, DLCO, and CT; tuberculosis, alpha-1 antitrypsin deficiency, and heart failure excluded. **S**
- Asthma well controlled (Asthma Control Test 20 or more) with no flare needing oral corticosteroids. In progress; target 1693-03-31. **S**
- No indoor solid-fuel smoke and less outdoor pollution exposure. In progress; target 1693-03-31. **S**
- Six-minute walk distance improved by at least 30 m after pulmonary rehabilitation. Outcome by 1692-06-18: 430 m before and 505 m after an eight-week program. **S**

## Medication changes

- Stopped: Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for aches or fever, no more than 3 g a day **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022), European Respiratory Society and American Thoracic Society
- WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021), World Health Organization
- Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020), European Respiratory Society
- AQI Basics (2026), United States Environmental Protection Agency (AirNow)
- Air Cleaners and Air Filters in the Home (2026), United States Environmental Protection Agency
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Asthma review in three months; zoster dose 2 in two to six months; spirometry within a year of the last. **S**

